Dosimetry for glass trans-arterial radioembolization (TARE) is commonly calculated via a uniform activity distribution model. Recent studies have demonstrated improved tumor response with increased dose to perfused area though no tumor dose threshold is established. This study evaluates dose to tumor and treatment response (mRECIST and LI-RADS criteria) after TARE for early-stage hepatocellular carcinoma (HCC) to determine a threshold tumor dose to predict a complete imaging response.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with A.
Contact A., search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack